Carmine N. Stengone - 31 Jan 2025 Form 4 Insider Report for Contineum Therapeutics, Inc. (CTNM)

Role
CEO and President, Director
Signature
/s/ Peter Slover, Attorney-in-Fact
Issuer symbol
CTNM
Transactions as of
31 Jan 2025
Net transactions value
$0
Form type
4
Filing time
31 Jan 2025, 16:35:27 UTC
Previous filing
12 Sep 2024
Next filing
02 Apr 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTNM Stock Option (right to buy) Award $0 +300,000 $0.000000 300,000 31 Jan 2025 Class A Common Stock 300,000 $9.79 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Options granted under the Issuer's 2024 Equity Incentive Plan. 25% of the option shares vest on January 1, 2026, and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's continuous service.